Literature DB >> 8504603

Giant cell tumor of the sacrum.

R E Turcotte1, F H Sim, K K Unni.   

Abstract

Twenty-six patients (18 women and eight men) with giant cell tumors of the sacrum were treated from 1960 through 1986. The mean age of the patients was 29 years. The follow-up duration averaged 7.8 years. A neurologic deficit was present in 88%. Sixteen patients had not had a previous operation. Ten patients were referred for local recurrence. Twenty-one patients had radiation therapy; malignant transformation later occurred in three. Three benign giant cell tumors metastasized to the lungs. The local recurrence rate for patients treated by curettage was 33%. Three patients died of tumor-related complications. At the completion of this study, two patients were alive with disease. The suggested initial treatment is complete curettage. Radiation therapy should be reserved for incomplete resection and local recurrence. Occasionally, patients may require wide resection, which may cause a severe neurologic deficit and compromise spinal stability.

Entities:  

Mesh:

Year:  1993        PMID: 8504603

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  24 in total

Review 1.  Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.

Authors:  Christopher Martin; Edward F McCarthy
Journal:  Iowa Orthop J       Date:  2010

2.  Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor.

Authors:  Pietro Ruggieri; Andreas F Mavrogenis; Giuseppe Ussia; Andrea Angelini; Panayiotis J Papagelopoulos; Mario Mercuri
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

3.  Conservative surgery in the treatment of giant cell tumor of the sacrum: 35 years' experience.

Authors:  Stepan V Domovitov; Chandhanarat Chandhanayingyong; Patrick J Boland; David G McKeown; John H Healey
Journal:  J Neurosurg Spine       Date:  2015-10-30

4.  Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision.

Authors:  L van der Heijden; M A J van de Sande; I C M van der Geest; H W B Schreuder; B J van Royen; P C Jutte; J A M Bramer; F C Öner; A P van Noort-Suijdendorp; H M Kroon; P D S Dijkstra
Journal:  Eur Spine J       Date:  2014-03-11       Impact factor: 3.134

5.  Preoperative embolization of primary bone tumors: A case control study.

Authors:  Roushan Jha; Raju Sharma; Shishir Rastogi; Shah Alam Khan; Arvind Jayaswal; Shivanand Gamanagatti
Journal:  World J Radiol       Date:  2016-04-28

6.  Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: A case report.

Authors:  Tetsuro Yamagishi; Hiroyuki Kawashima; Akira Ogose; Taro Sasaki; Tetsuo Hotta; Shoichi Inagawa; Hajime Umezu; Naoto Endo
Journal:  Oncol Lett       Date:  2015-11-04       Impact factor: 2.967

7.  Embolization of musculoskeletal bone tumors.

Authors:  Richard J T Owen
Journal:  Semin Intervent Radiol       Date:  2010-06       Impact factor: 1.513

8.  Selective arterial embolisation for bone tumours: experience of 454 cases.

Authors:  G Rossi; A F Mavrogenis; E Rimondi; F Ciccarese; C Tranfaglia; B Angelelli; G Fiorentini; T Bartalena; C Errani; P Ruggieri; M Mercuri
Journal:  Radiol Med       Date:  2011-03-19       Impact factor: 3.469

Review 9.  Axial giant cell tumor - current standard of practice.

Authors:  Navaneeth Kamath; Jasmine Agarwal; Ashish Gulia
Journal:  J Clin Orthop Trauma       Date:  2019-10-09

10.  Risk factors for blood loss during sacral tumor resection.

Authors:  Xiaodong Tang; Wei Guo; Rongli Yang; Shun Tang; Tao Ji
Journal:  Clin Orthop Relat Res       Date:  2008-09-10       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.